Get to know our clinical trials
Multicenter extension clinical trial to evaluate the long-term safety and tolerability of open-label iptacopan in adult participants with primary IgA nephropathy who have completed a pivotal study of iptacopan in IgA nephropathy
THE PURPOSE OF THE STUDY IS TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF IPTACOPAN IN PARTICIPANTS WITH PRIMARY IGA NEPHROPATHY WHO ARE RECEIVING OPEN-LABEL IPTACOPAN AFTER COMPLETING A NOVARTIS-SPONSORED PIVOTAL STUDY OF IPTACOPAN IN IGA NEPHROPATHY
Technical Summary
- A MULTICENTER EXTENSION PROGRAM TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF OPEN-LABEL IPTACOPAN IN ADULT PARTICIPANTS WITH PRIMARY IGA NEPHROPATHY WHO HAVE COMPLETED A NOVARTIS-SPONSORED PIVOTAL STUDY OF IPTACOPAN IN IGA NEPHROPATHY
- Code EudraCT: 2023-508690-92-00
- Protocol number: CLNP023A2002B
- Promoter: Novartis Farmaceutica
- Molecule/Drug: iptacopán
- Link to Clinical Trials
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.